Recon: Novo Nordisk's next-generation obesity therapy falters in diabetes study; Sun Pharma to acquire Checkpoint Therapeutics for $355M

• On path to likely confirmation as NIH director, Bhattacharya toes the party line (STAT)
• US FDA to hold off action on weight-loss drug copies pending court ruling (Reuters)
• Mayo Clinic’s partnership with dairy poses conflict of interest, critics say (STAT)
• How will the Center for Biologics Evaluation and Research change under RFK Jr.? (STAT)
• At ‘Stand Up for Science’ rally, Francis Collins warns major NIH research programs ‘at severe risk’ (STAT)
• Compounders’ motion for preliminary injunction denied in case over tirzepatide shortage (Endpoints)
• Exclusive: FDA blocks drug and device reviewers from taking HHS' buyout offer (Endpoints)

• Novo Nordisk shares drop after next-gen obesity drug disappoints in diabetes trial (STAT) (Reuters)
• A U.K. trade group is due to lift its suspension of Novo Nordisk, but critics cite a lack of transparency (STAT)
• UK MHRA Holds 2025 Device Registration Fee Increase (MedTech Insight)
• Emergent sells once-troubled manufacturing site to Indian CDMO (Endpoints)
• Eli Lilly plans to launch weight-loss drug in emerging markets this year (Reuters)
• India's Syngene International acquires first US biologics facility for $36.5 mln (Reuters)
• India's Sun Pharma to acquire Checkpoint Therapeutics for $355 million (Reuters)

• Mineralys Therapeutics stock soars on blood pressure drug data (STAT)
• Beam Therapeutics says CRISPR treatment shows encouraging results in lung condition (STAT)
• BioNTech's shares dip after posting lukewarm revenue guidance (Endpoints)
• Mired in low expectations, Novo braces for upcoming CagriSema head-to-head trial (Endpoints)
• J&J, Protagonist outline first IBD win for oral IL-23 with $5B+ sales potential (Endpoints)
• Trevi’s mid-stage chronic cough data meet ‘home run’ scenario, stock soars (Endpoints)
• UK's Alliance Pharma accepts DBAY's sweetened final offer (Reuters)

• For Google, health equity becomes ‘health optimization’ as Trump targets DEI (STAT)
• New Flagship startup aims to trailblaze ‘AI science factories’ (Endpoints)
• Former an Diagnostics CEO pleads guilty over lead-test device defect (Reuters)
• New FDA pulse oximetry guidelines could stall under Trump (MedTech Dive)
• Orthofix’s fired execs’ lewd, ‘graphic’ texts surface in legal battle (MedTech Dive)
• Dexcom receives warning letter based on FDA inspections of 2 plants (MedTech Dive)
• The top 3 impacts of Trump’s health data purge (MedTech Dive)

• UnitedHealth’s deals and how big hospitals are faring (STAT)
• Scientists’ suit against top academic publishers lays bare deep frustration over unpaid peer review (STAT)
• Tariffs will make it even more expensive for Americans to eat healthy (STAT)
• After-hours CDC email sparked chaos at universities. It turned out to be a mistake (STAT)
• NIH abruptly terminates millions in research grants, defying court orders (STAT)
• Doctors push back as parents embrace Kennedy and vitamin A in Texas measles outbreak (Reuters)